Open: US FDA’s Docket For NAC Comments, And CRN On Its Options To Contest Enforcement
Executive Summary
Docket remained closed for a few days after FDA asked for additional comments on whether to conduct NAC rulemaking. FDA, says CRN, turned DSHEA on its head in 2020 when it said NAC was approved as a drug and couldn’t be used as a dietary ingredient.
You may also be interested in...
US Dietary Ingredient ‘Preclusion’ Swings On Information Closed To Supplement Industry – CRN
Trade group contends FDA’s misuse of regulation prohibiting any substance studied or approved as a drug in US from being used as dietary ingredients undermines innovation in supplement industry and is detrimental to consumer choice and health.
It’s Official: US Enforcement Discretion For NAC In Supplements, And Regulatory Options For FDA
Draft guidance states enforcement discretion allowing sales of N-acetyl-L-cysteine supplements which FDA in 2020 ordered firms to halt selling due to its use as a drug ingredient. However, NAC supplements, as they have remained since 2020, were available to US consumers when draft was published.
NAC Gains Tentative Safety Clearance As US Industry Contests FDA's Attempt To Remove It
FDA answers reach supplement industry sounding like a siren that the agency may take same enforcement step it has with NAC with other ingredients long used in supplements. Answers also might not be enough to convince firms to return NAC-containing supplements to their lineups.